Pfizer reportedly scrapped development of a once-daily GLP-1 pill after a person involved in the drug’s trial suffered a liver injury.

Pfizer is reversing course on developing a weight-loss pill after a patient in its trial suffered what's believed to be drug-induced liver injury.

The Dow Jones Industrial Average added 312.08 points, or 0.78%, to close at 40,524.79. The Nasdaq Composite rose 0.64% to end ...

The decision to stop developing danuglipron adds to a string of setbacks in the pharmaceutical giant’s bid to win a slice of ...

Swiss pharmaceutical giant Novartis announced Thursday that it plans to build a $1.1 billion research hub in San Diego as ...

It is part of a planned $23 billion investment over the next five years aimed at expanding its U.S.-based infrastructure.

Pfizer is officially bidding adieu to its sprawling research site in San Diego as it readjusts its local footprint and moves into a new site. | The company is moving its oncology R&D digs in San Diego ...

Pfizer sold the five-building facility on Science Center Drive in Torrey Pines to BioMed Realty, a San Diego-based firm owned ...

SAN DIEGO, CA / ACCESS Newswire / April 9, 2025 / Robbins LLP reminds stockholders that a class action was filed against ...

UC San Diego and Stanford University researchers have created a comprehensive map of the human U2OS cell. The map revealed ...

SAN DIEGO, April 08, 2025 (GLOBE NEWSWIRE ... Earlier in his career, Dr. Banerjee supported the clinical development of Xeljanz® (tofacitinib) at Pfizer Inc., and early development activities of ...

BioMed Realty has made a big long-term bet on demand in San Diego’s life science sector with a $255M acquisition of Pfizer’s ...